RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
1-Year Return
18.15%
This Quarter Return
+1.96%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$7.51B
AUM Growth
-$1.16B
(-13%)
Cap. Flow
+$76.9M
Cap. Flow
% of AUM
1.02%
Top 10 Holdings %
Top 10 Hldgs %
57.63%
Holding
98
New
17
Increased
9
Reduced
16
Closed
9
Top Buys
| 1 |
SEPN
Septerna, Inc. Common Stock
SEPN
|
$160M |
| 2 |
SPDR S&P Biotech ETF
XBI
|
$111M |
| 3 |
Arcellx
ACLX
|
$71.8M |
| 4 |
Janux Therapeutics
JANX
|
$64.2M |
| 5 |
Ascendis Pharma
ASND
|
$55.4M |
Top Sells
| 1 |
Biogen
BIIB
|
$230M |
| 2 |
VRNA
Verona Pharma
VRNA
|
$151M |
| 3 |
Evolent Health
EVH
|
$55.5M |
| 4 |
CG Oncology
CGON
|
$52.7M |
| 5 |
Recursion Pharmaceuticals
RXRX
|
$51.8M |
Sector Composition
| 1 | Healthcare | 98.36% |
| 2 | Financials | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Sera Prognostics
SERA
$130M
| $24.7M | 0.33% |
3,032,808
| – | – |
|
|
JBIO
52
Jade Biosciences, Inc. Common Stock
JBIO
$254M
| $24.4M | 0.32% |
262,631
| – | – |
|
53
EyePoint Pharmaceuticals
EYPT
$819M
| $23.7M | 0.32% |
+3,181,818
| New | +$23.7M |
|
54
Larimar Therapeutics
LRMR
$331M
| $23.4M | 0.31% |
6,045,351
| – | – |
|
|
CBLL
55
CeriBell, Inc. Common Stock
CBLL
$452M
| $21.3M | 0.28% |
+824,582
| New | +$21.3M |
|
56
Travere Therapeutics
TVTX
$1.89B
| $20M | 0.27% |
+1,150,000
| New | +$20M |
|
57
Enliven Therapeutics
ELVN
$1.19B
| $19.1M | 0.25% |
848,986
-212,247
| -20% | -$4.78M |
|
58
Taysha Gene Therapies
TSHA
$889M
| $18.8M | 0.25% |
10,872,503
| – | – |
|
59
Alector
ALEC
$285M
| $18.3M | 0.24% |
+9,695,228
| New | +$18.3M |
|
60
Protara Therapeutics
TARA
$122M
| $18M | 0.24% |
3,400,000
+1,500,000
| +79% | +$7.92M |
|
61
C4 Therapeutics
CCCC
$190M
| $17.6M | 0.23% |
4,878,000
| – | – |
|
62
Solid Biosciences
SLDB
$433M
| $17.3M | 0.23% |
4,330,446
| – | – |
|
63
Pliant Therapeutics
PLRX
$100M
| $16.9M | 0.22% |
1,281,000
| – | – |
|
|
DRUG
64
Bright Minds Biosciences
DRUG
$312M
| $16.6M | 0.22% |
+460,829
| New | +$16.6M |
|
|
ITOS
65
DELISTED
iTeos Therapeutics
ITOS
| $16.1M | 0.21% |
2,092,259
-1,092,452
| -34% | -$8.39M |
|
|
BCYC
66
Bicycle Therapeutics
BCYC
$483M
| $15.3M | 0.2% |
1,093,477
-1,159,523
| -51% | -$16.2M |
|
67
Eledon Pharmaceuticals
ELDN
$156M
| $14.7M | 0.2% |
+3,566,338
| New | +$14.7M |
|
68
Insmed
INSM
$30.1B
| $13.8M | 0.18% |
200,000
| – | – |
|
69
Xencor
XNCR
$597M
| $13.2M | 0.18% |
575,000
| – | – |
|
70
Immatics
IMTX
$695M
| $12.4M | 0.17% |
1,750,000
| – | – |
|
71
Aclaris Therapeutics
ACRS
$224M
| $11.6M | 0.15% |
+4,666,667
| New | +$11.6M |
|
72
Monopar Therapeutics
MNPR
$240M
| $11.2M | 0.15% |
+511,207
| New | +$11.2M |
|
|
THRD
73
DELISTED
Third Harmonic Bio
THRD
| $9.88M | 0.13% |
960,620
-320,206
| -25% | -$3.29M |
|
74
Werewolf Therapeutics
HOWL
$61.7M
| $9.09M | 0.12% |
6,144,881
| – | – |
|
75
Arvinas
ARVN
$559M
| $8.08M | 0.11% |
421,348
| – | – |
|